<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In recent years, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), once a uniform disease with well-understood <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, has been divided into at least five different subgroups with distinct precursor lesions, pathways of <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, morphological, and molecular characteristics </plain></SENT>
<SENT sid="1" pm="."><plain>Moreover, new therapeutic concepts with 'targeted' substances have added to the complexity of the management of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>The clinical value of biomarkers in advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> is indisputable ever since activating mutations of the KRAS oncogene have been shown to predict resistance to anti-epidermal growth factor receptor antibodies </plain></SENT>
<SENT sid="3" pm="."><plain>Prognostic biomarkers predicting patient outcomes and predictive biomarkers forecasting response to a certain therapy may help us to improve therapeutic agent selection and patient management with the ultimate goal of maximizing the benefit of treatment and minimizing toxicity </plain></SENT>
<SENT sid="4" pm="."><plain>Biomarkers with known implications in advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> will be discussed in this paper </plain></SENT>
</text></document>